Participated · Seed · Feb 2026

xWatts is a London-based software company that builds an AI-driven energy management platform for large, complex real-estate portfolios. Unlike solutions that merely analyse data, its software connects directly to on-site systems—such as HVAC, solar arrays, and combined heat-and-power units—to model facilities in real time and automatically optimise both generation and demand. The technology has already been deployed in healthcare, education and manufacturing facilities, where it has delivered reductions in energy use, operating costs and carbon emissions. Target customers are owners and operators of non-domestic buildings across Europe, a segment with high energy intensity and rising decarbonisation pressure. The company’s vision is to decarbonise these assets in an intelligent, automated and scalable way. Proceeds from its latest £1.6 million seed round will fund further product development and expansion in key European markets. No revenue or user figures were disclosed, but the company positions its platform as a mission-critical control layer rather than a passive analytics tool.

Participated · Seed · Nov 2025

Cordance Medical is building a noninvasive focused ultrasound system designed to temporarily and safely open the blood-brain barrier (BBB), enabling drugs and other therapeutic agents to reach the brain more effectively. The platform employs patient-specific signal processing with real-time monitoring of BBB opening and avoids the need for head fixation or live imaging, targeting practical outpatient use. While its first clinical application is brain cancer, the company envisions broader utility across multiple neurological conditions. Cordance has already secured FDA Breakthrough Device Designation in neuro-oncology and received a grant from the National Cancer Institute at the NIH to help fund its first-in-human U.S. trial. Proceeds from its recent seed financing will advance this clinical study and further product development. Based in Mountain View, California, the firm is supported by a strong syndicate of healthcare and neuro-oncology investors. The company has not disclosed revenue, user numbers, or other operating metrics.

Participated · Series A · Dec 2024

Abselion develops automated analytical instrumentation, notably its Amperia benchtop system, to simplify at-line protein analytics for biologics development and production. The company’s RED (redox-electrochemical-detection) technology enables sensitive, specific measurement of antibodies, AAVs and other proteins directly from crude samples, producing results in as little as one minute. Abselion positions the Amperia to deliver on-the-spot process insights that improve efficiency and accuracy in life‑science research and bioprocessing. The product targets applications across development and production workflows for biologics such as antibodies and viral vectors. The company is led by CEO Ruizhi Wang and is based in Cambridge, UK. Recent fundraising is intended to support commercialisation and to expand the Amperia system’s capabilities. HexagonFab is a University of Cambridge spin-out that develops affordable, convenient analytical lab instruments to simplify biomolecular interaction analysis for pharma research and manufacturing. Its first product, the Bolt, is a handheld device that uses electrical detection with a graphene-based semiconductor sensor to measure protein, antibody and small-molecule affinity and kinetics down to low nanomolar concentrations. The Bolt provides real-time signals, requires no installation, and delivers results in hours rather than days, enabling on-site testing by researchers and manufacturing quality-control teams. HexagonFab positions the Bolt to reduce costs, delays and failures in biopharmaceutical discovery and production, accelerating development of novel medicines for small patient populations. Proceeds from the seed round will be used to grow the team, complete development of the Bolt, and launch the product commercially. The company describes its instruments as convenient, accessible and affordable for scientists, researchers, and drug manufacturers.

Led · Series C · Aug 2024

Healx uses AI and a "biomedical knowledge graph" built from public and proprietary biomedical data to identify links between existing compounds and rare diseases, pairing digital biology and digital chemistry teams to match disease signatures with small molecules. The company’s platform applies computational techniques such as virtual screening and generative chemistry to prioritize de‑risked drug candidates drawn from compounds at various development stages or previously shelved. Its lead clinical program is HLX-1502 for neurofibromatosis Type 1 (NF1), an oral tablet that Healx says was derived from an existing compound and for which the company owns patents covering the NF1 indication and has received U.S. regulatory exclusivity. Healx has received FDA clearance to start Phase 2 U.S. trials for HLX-1502, expected to begin by the end of 2024, and anticipates initial clinical readouts potentially in the first half of 2026. The company is also in earlier AI-discovery or preclinical work across oncology, renal and neurology, and is testing whether the NF1 candidate works on other nerve-related diseases. Financially, Healx raised a $47M Series C and had previously raised about $68M (including a $56M Series B in 2019); it also recently announced an investment arrangement with the Children’s Tumor Foundation that will provide milestone-driven payments toward trials. The firm trimmed staff during the recent downturn (a reduction the company framed as ~45% last year) and now counts roughly 55 employees, roughly half focused on coding and ML/computational biology. Healx combines a proprietary AI-powered drug discovery platform with drug development expertise to identify treatments for rare diseases. Its lead candidate for Neurofibromatosis Type 1, HLX-1502, was identified via Healx's AI-informed approach and is on course to enter a Phase 2 clinical trial in the coming months. Healx plans to develop HLX-1502 for both plexiform and cutaneous NF1 subtypes. The company has an established partnership with the Children's Tumor Foundation (CTF) dating to 2020, leveraging CTF's preclinical, clinical and patient community knowledge. Healx has raised over $100 million to date and added a dozen projects to its risk‑balanced therapeutic portfolio. The company was founded in Cambridge, UK by Dr Tim Guilliams and Dr David Brown and positions itself as a patient‑inspired, mission‑driven techbio organisation focused on rare-disease impact. Healx applies AI and a hypothesis-free biomedical knowledge graph to identify new uses for approved drugs, focusing on rare genetic diseases. The company prioritizes drug repurposing and combination predictions rather than developing de novo molecules. It works closely with patient groups and plans to scale discovery via a global Rare Treatment Accelerator. Healx aims to progress 100 rare disease treatments toward the clinic by 2025 and to move predicted treatments into clinical testing within 24 months. Co-founder Dr. David Brown, who has previously invented drugs including work on Viagra, is cited for having contributed to products that generated roughly $40 billion in revenue. The company validated its approach with the FRAXA Research Foundation and expects further clinical programmes to begin later in 2020. Healx develops treatments for rare diseases by combining artificial intelligence and machine learning with deep pharmacological expertise and extensive patient engagement. Its core asset, HealNet, is a knowledge base mapping over one billion unique disease, patient and drug interactions, built from scientific literature, patents, clinical trials, symptoms, drug targets, multi-omic data and chemical structures. The company was founded in 2014 by Dr Tim Guilliams, Dr David Brown and Dr Andreas Bender and is based in Cambridge, UK. Healx intends to use the funds to more than double its multidisciplinary team of software engineers, data scientists, pharmacologists and drug development experts drawn from the Cambridge ecosystem. The company plans to expand its AI and machine-learning technologies to accelerate discovery and development of rare-disease treatments. Healx recently secured a $10M Series A to support these growth plans. Healx, based in Cambridge, UK and led by CEO Tim Guilliams, applies advanced data analytics—including machine learning, computational biology techniques and scientific literature analysis—to identify novel drug applications for rare diseases. The company focuses on repurposing existing drugs to address conditions that collectively afflict some 350 million people worldwide. Its model engages directly with patient advocacy groups to guide personalized approaches and research priorities. Healx has won contracts from major medical foundations in the US and Europe to find drug candidates for conditions including childhood diseases, Barth syndrome and Fragile‑X. The company intends to use newly raised funds to expand its technology platform and accelerate its drug review process to identify treatments for additional illnesses. The business emphasizes accelerating drug candidate identification through computational and literature-driven methods.

Participated · Series A · Apr 2024

Rubedo Life Sciences develops novel small-molecule therapies engineered to selectively target various types of senescent cells using its ALEMBIC™ drug discovery platform. Its lead candidate, RLS-1496, is being advanced into Phase 1 studies for chronic atopic dermatitis and chronic psoriasis. The company is also developing programs targeting senescent cells in pulmonary diseases, including a program for idiopathic pulmonary fibrosis (IPF) that received a substantial CIRM grant last year. Rubedo’s pipeline targets multiple therapeutic areas tied to aging biology, such as pulmonary, dermatological, oncological, neurodegenerative and fibrotic disorders. The company is led by CEO & Co‑Founder Marco Quarta with Ali Siam as Chief Business Officer and is based in Sunnyvale, California. Financially, Rubedo recently closed a $40M Series A to fund its clinical and preclinical programs. Rubedo Life Sciences develops novel senolytic small‑molecule prodrugs via its proprietary ALEMBIC drug discovery platform to selectively target pathologic senescent cells that drive age‑related diseases. The company is advancing a pharmacological regenerative program for idiopathic pulmonary fibrosis (IPF), aiming to characterize senescent lung stem and progenitor cells and to screen a library of senolytic prodrugs on IPF primary cells. Rubedo plans to nominate a lead senolytic development candidate and to develop a clinical study using a humanized IPF model. The program is supported by a $1.45M award from the California Institute for Regenerative Medicine (CIRM). Rubedo has partnered with Cedars‑Sinai for the IPF research, with Cory Hogaboam, PhD, leading the Cedars‑Sinai effort. The company is based in Sunnyvale, CA, and is led by CEO and co‑founder Marco Quarta, PhD. Rubedo Life Sciences develops novel small-molecule therapies engineered to selectively target senescent, pro-inflammatory and pro-fibrotic cell populations using its proprietary ALEMBIC™ drug discovery platform. The company’s lead programs focus on respiratory diseases with high unmet need, including idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD). Rubedo also has preclinical candidates in oncology and plans to pursue programs in neurodegenerative conditions, skeletal muscle disorders and other age-related diseases. The company plans to advance several compounds into IND-enabling studies in pulmonary diseases starting next year. Rubedo is based in Sunnyvale, California. It recently closed a seed financing to accelerate development of its clinical pipeline.